Hormone replacement and the risk of breast cancer in Turner's syndrome [22]

New England Journal of Medicine

Volumn 355, Issue 24, 2006, Pages 2599-2600

  Bösze, Peter ^a   Tóth, András ^b   Török, Miklós ^b  

^a Saint Stephen Hospital   (Hungary)

^b National Health Center   (Hungary)

Author keywords

[No Author keywords available]

Indexed keywords

ESTROGEN; PROGESTERONE;

BREAST CANCER; BREAST DEVELOPMENT; HORMONE SUBSTITUTION; HUMAN; LETTER; LOW DRUG DOSE; MAMMOGRAPHY; MENSTRUATION; POSTMENOPAUSE; PRIORITY JOURNAL; RISK FACTOR; TURNER SYNDROME;

ADULT; BREAST NEOPLASMS; ESTROGEN REPLACEMENT THERAPY; ESTROGENS; FEMALE; GONADOBLASTOMA; HUMANS; LONGITUDINAL STUDIES; OVARIAN NEOPLASMS; PROGESTERONE; RISK FACTORS; TURNER SYNDROME;

EID: 33845488141     PISSN: 00284793     EISSN: 15334406     Source Type: Journal    
DOI: 10.1056/NEJMc062795     Document Type: Letter

References (4)

1. Bösze P, László J. The streak gonad syndrome. Obstet Gynecol 1979;54:544-8.
2. Rossouw JE, Anderson GL, Prentice RL, et al. Risk and benefits of estrogen plus progestin in healthy postmenopausal women: principal results from the Women's Health Initiative randomized controlled trial. JAMA 2002;288:321-33.
3. Warren MP, Chua A. Appropriate use of estrogen replacement therapy in adolescents and young adults with Turner syndrome and hypopituitarism in light of the Women's Health Initiative. Growth Horm IGF Res 2006;16:Suppl A:S98-S102.
4. Gaál M, Tóth A, Bõsze P, László J. 46,X,i(Xq)/45,X mosaicism with gonadal dysgenesis associated with 21p-. Clin Genet 1984; 25:79-83.